Investigational drug · Phase 2
RSV vaccine candidate
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Syncytial Virus Infection, Healthy Volunteers, Respiratory Syncytial Virus Immunization.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
19
Any phase or sponsor naming "RSV vaccine candidate"
First trial start
2022
Nov 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RSV vaccine candidate", any sponsor or status.
- Phase 116
Conditions studied
As listed on its trial records.
- Respiratory Syncytial Virus Infection
- Healthy Volunteers
- Respiratory Syncytial Virus Immunization
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "RSV vaccine candidate" as an intervention, largest first.
- Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07810010 · 8,000 participants (planned) · Start Sep 9, 2026 · Primary completion Jul 3, 2028
Drug: Bivalent RSV+HMPV protein vaccine; Placebo · For: Respiratory Syncytial Virus; Human Metapneumovirus; Healthy Volunteers
Sites: Bruse, Australia; Blacktown, Australia; Maroubra, Australia · 21 sites in all
- Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and OlderPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06251024 · 4,541 participants · Start Apr 2, 2024 · Primary completion Mar 11, 2025
Drug: RSV vaccine candidate; Placebo · For: Respiratory Syncytial Virus Infection; Healthy Volunteers
Sites: Botany, Australia; Sippy Downs, Australia; Southport, Australia · 25 sites in all
- Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and OlderPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07734649 · 2,400 participants (planned) · Start Jul 22, 2026 · Primary completion May 3, 2028
Drug: RSV+HMPV vaccine; Control Vaccine 3 and 3 more · For: Respiratory Syncytial Virus Immunization; Human Metapneumovirus Immunization; Healthy Volunteers
Sites: Gadsden, Alabama; Vestavia Hills, Alabama; Huntington Beach, California · 50 sites in all
- Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and OlderPivotal-lookingActive, not recruiting
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06686654 · 1,530 participants · Start Nov 11, 2024 · Primary completion Jan 18, 2027
Drug: Investigational hMPV/RSV vaccine; Investigational hMPV vaccine (monovalent) and 4 more · For: Human Metapneumovirus Immunization; Respiratory Syncytial Virus Immunization
Sites: Phoenix, Arizona; Garden Grove, California; Gardena, California · 24 sites in all
- A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT05886777 · 1,142 participants · Start Jun 5, 2023 · Primary completion Jan 1, 2024
Drug: Combination [RSVpreF+BNTb162b2]; Bivalent BNT162b2 (original/Omi BA.4/BA.5) and 3 more · For: Healthy Participants
Sites: Dublin, California; Huntington Beach, California; Lake Forest, California · 37 sites in all
- Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and OlderPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT05639894 · 865 participants · Start Nov 17, 2022 · Primary completion May 2, 2025
Drug: RSV vaccine candidate · For: Respiratory Syncytial Virus Immunization
Sites: Huntsville, Alabama; Mesa, Arizona; Peoria, Arizona · 33 sites in all
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine CandidatePivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06134648 · 646 participants · Start Nov 1, 2023 · Primary completion Feb 27, 2026
Drug: RSV/hMPV vaccine candidate Dose L; RSV/hMPV vaccine candidate Dose A and 2 more · For: Respiratory Syncytial Virus Infection; Healthy Volunteers; Human Metapneumovirus
Sites: Los Alamitos, California; Los Angeles, California; Rolling Hills Estates, California · 13 sites in all
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older AdultsPivotal-lookingActive, not recruiting
Clover Biopharmaceuticals AUS PtyIndustry
NCT06984094 · 612 participants · Start Jun 18, 2025 · Primary completion Mar 2028
Drug: SCB-1019T; SCB-1022 and 2 more · For: RSV Infection; Human Metapneumovirus Infection; Parainfluenza Infection
Sites: Adelaide, Australia; Melbourne, Australia; Perth, Australia
- Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and OlderPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06237296 · 558 participants · Start Jan 23, 2024 · Primary completion Feb 11, 2025
Drug: RSV/hMPV mRNA LNP 1; RSV/hMPV mRNA LNP 2 and 2 more · For: Respiratory Syncytial Virus Infection; Healthy Volunteers; Metapneumovirus Infection
Sites: Gardena, California; Hallandale, Florida; Meridian, Idaho · 17 sites in all
- Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and OlderPivotal-lookingCompleted
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
NCT06604767 · 390 participants · Start Sep 17, 2024 · Primary completion Mar 24, 2026
Drug: parainfluenza virus type 3 vaccine (PIV3); RSV/hMPV/PIV3 vaccine and 3 more · For: Respiratory Syncytial Virus Infection; Metapneumovirus Infection; Parainfluenzae Virus Infection
Sites: Blacktown, Australia; Botany, Australia; Brookvale, Australia · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Immunogenicity and shedding of live-attenuated intranasal respiratory syncytial virus vaccine in children aged 6-18 months by baseline serostatus: a multicentre, randomised, placebo-controlled, phase 1/2 trial.
Idoko OT, Vargas SL, Bueso A, et al. · Lancet Microbe 2026
- Highly efficient and durable Th1-biased protective immunity from a novel mRNA vaccine against RSV via AI-assisted antigen screening.
Dong K, Liu F, Zhang M, et al. · Mol Ther 2026
- Immunogenicity of a Recombinant MVA Vector Vaccine Expressing the Prefusion RSV F Protein in Balb/c Mice.
Miao J, Liu M, Zhang Q, et al. · Vaccines (Basel) 2026
- Evaluation of the Safety and Efficacy of the Respiratory Syncytial Virus FG Chimeric Vaccine KD-409 in Rodent Models for Maternal and Pediatric Vaccination.
Yamaue R, Terashima M, Soejima K, et al. · Vaccines (Basel) 2025
- Developing an eVLP mRNA vaccine for respiratory syncytial virus with enhanced pre-fusion targeting humoral responses.
Sun L, Huang M, Feng S, et al. · J Virol 2025
- Nanoparticle vaccine based on the pre-fusion F glycoprotein of respiratory syncytial virus elicits robust protective immune responses.
Hu Z, Tian S, Zhou Y, et al. · J Virol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.